Mid-frequency acoustic tracking of breaking waves.

Large surface wave breaking events in deep water are acoustically detectable by beamforming at 5-6 kHz with a mid-frequency planar array located 130 m below the surface. Due to the array's depth and modest 1 m horizontal aperture, wave breaking events cannot be tracked accurately by beamforming alone. Their trajectories are estimated instead by splitting the array into sub-arrays, beamforming each sub-array toward the source, and computing the temporal cross-correlation of the sub-array beams.

Females show worse functional outcome and quality of life compared to males 2 years after meniscus surgery: Data analysis from the German Arthroscopy Registry.

Purpose: The purpose of this study was to investigate the impact of sex on knee function, activity and quality of life following meniscus surgery using data from the German Arthroscopy Registry.

Methods: This is a retrospective cohort study with data collected between 2017 and 2022. Patient-reported outcome measures (PROMs), namely Knee Injury and Osteoarthritis Outcome Score (KOOS), EuroQol Visual Analogue Scale (EQ Scale), and Marx Activity Rating Scale (MARS), were collected preoperatively and at 6, 12 and 24 months postoperatively.

Mid-frequency acoustic localization of breaking waves.

During an experiment in deep water off the coast of Southern California, wind speeds ranged from 10 to 15 m/s and wind forcing produced large breaking waves. A mid-frequency vertical planar hydrophone array recorded underwater ambient noise while an airplane equipped with a high-resolution video camera captured images of the sea surface above the array. Beams of ambient noise between 5 and 6 kHz were projected onto the sea surface and synchronized in space and time with the aerial images.

Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.

We evaluated two formulations of a new combined Haemophilus influenzae type b (Hib)-meningococcal serogroup C (MenC)-tetanus toxoid (TT) conjugated vaccine and two formulations of a new MenC-TT vaccine (trials 711202/001 and 711202/008; clinical trial register numbers NCT00135486 and NCT00135564 [www.ClinicalTrials.gov]).